

# Supporting Information 1

## Machine learning of designed translational control allows predictive pathway optimisation in *Escherichia coli*


Adrian J. Jervis<sup>†</sup>, Pablo Carbonell<sup>†</sup>, Maria Vinaixa<sup>†</sup>, Mark Dunstan<sup>†</sup>, Katherine Hollywood<sup>†</sup>, Nicholas Rattray<sup>‡</sup>, Christopher J. Robinson<sup>†</sup>, Cunyu Yan<sup>†</sup>, Neil Swainston<sup>†</sup>, Andrew Currin<sup>†</sup>, Rehana Sung<sup>†</sup>, Helen Toogood<sup>†</sup>, Sandra Taylor<sup>†</sup>, Jean-Loup Faulon<sup>†§</sup>, Rainer Breitling<sup>†</sup>, Eriko Takano<sup>†</sup>, Nigel S. Scrutton<sup>†\*</sup>

## Contents

S1. <i>In vivo</i> monoterpenoid screening pipeline.....	2
S2. Identification of optimal inducer concentrations .....	3
S3. Re-screening of pGLlib high producers .....	4
S4. Comparison of RBS sequences for pGLlib high/low producers .....	5
S5. Validation of machine learning for pGLlib .....	6
S6. Genetic organisation of the pMVA series.....	7
S7. pMVA plasmid series (S)-limonene production .....	8
S9. Validation of machine learning for pMVA2lib1.....	10
S10. Re-screening of pMVA2lib high producers from 1 ml screen .....	11
Table S1. Enzymes used in this study.....	15
Table S3. Machine learning validation statistics .....	16
Table S5. Oligos used in this study .....	17
Table S6. Plasmids and strains used in this study .....	19
References .....	20

30 **S1. In vivo monoterpenoid screening pipeline**

31




42

43 **Figure S1.** Schematic of the *in vivo* monoterpenoid screening pipeline for *E. coli*. The pipeline uses 96-well  
44 plates and is designed to employ robotic liquid handling platforms to process samples simultaneously. Symbols  
45 indicate steps which are carried out manually (hand/spanner) or automated (cogs). Approximate time  
46 requirements for each step are also indicated. Typically 3 plates (288 samples) can be processed per day, per  
47 robot.

48

49 **S2. Identification of optimal inducer concentrations**

50




51

52 **Figure S2.** Identification of optimal of inducer concentrations for limonene production during plate-based  
53 fermentation. *Escherichia coli* DH10 $\beta$  cells transformed with plasmids pMVA and pGL were grown in a 96-  
54 deepwell block in a biphasic media as described in the Methods section. Triplicate wells were induced with  
55 different concentrations of the inducers Isopropyl- $\beta$ -D-thiogalactoside (IPTG) and anhydro-tetracycline (aTet).  
56 Titres are the average of 3 biological replicates and are displayed as the concentration in the organic phase.

57

58 **S3. Re-screening of pGLlib high producers**

59  
60  
61



62  
63  
64 **Figure S3.** Re-screening of the high-producing variants from pGLlib. Plasmid DNA from the top 24 producers  
65 in the pGLlib screen (Fig. 1) was purified and co-transformed with pMVA into fresh cells for testing in  
66 triplicate. The median fold-change in limonene production and upper/lower quartiles are indicated.  
67

68 **S4. Comparison of RBS sequences for pGLlib high/low producers**

69  
70  
71

A.



B.




72  
73

74 **Figure S4.** Comparison of the frequency of the variable nucleotides of RBSs in library pGLlib. The sequence  
75 patterns are displayed for the A) low producers (bottom quartile) and B) high producers (upper quartile) for the  
76 two genes *trAg-gpps* and *trMs-limS*. Sequence logos were generated through the weblogo service  
77 (weblogo.berkeley.edu).

78

79 **S5. Validation of machine learning for pGLlib**

80




81

82 **Figure S5.** Validation of the machine learning model for library pGLlib. The observed levels of limonene  
83 production (x- axis) are compared with predicted levels (y- axis) in fold change (FC) for each RBS combination  
84 using leave-one-out cross-validation with a resulting performance of  $Q^2 = 0.87$ . The blue dashed line is the  
85 linear fitting of the points.

86

87 **S6. Genetic organisation of the pMVA series**

88




103 **Figure S6.** Genetic organisation of the pMVA series of plasmids. Members differ through the position and

104 identity of gene promoters.

105

106 **S7. pMVA plasmid series (S)-limonene production**




122 **Figure S7.** Screening of the pMVA series of plasmids co-expressed with plasmid pGL403. Limonene  
123 production titres from triplicate cultures containing the indicated pMVA variant (red) compared to the original  
124 plasmid pMVA (gray) are displayed as fold-change (FC). Boxplots indicate the median, and upper/lower  
125 quartiles.


126

127 **S8. Comparison of RBS sequences for pMVA2lib1 high/low producers**  
128

A.



B.




129  
130 **Figure S8.** Comparison of the frequency of variable nucleotides distribution at RBS positions in the sequenced  
131 high and low producer variants of pMVA2lib1. A) Distribution for the *Ef-mvaE*, *Ef-mvaS*, *Sp-mvaK1* and *Ec-idi*  
132 RBSs for low producers in the pMVA2 library ( $FC <$  lower quartile); B) Distribution for the *Ef-mvaE*, *Ef-mvaS*,  
133 *Sp-mvaK1* and *Ec-idi* RBS sequences for high producers in the pMVA2 library ( $FC >$  upper quartile). Sequence  
134 logos were generated through the weblogo service (weblogo.berkeley.edu).

135

136 **S9. Validation of machine learning for pMVA2lib1**

137



138  
139


140 **Figure S9.** Model validation for library pMVA2lib1. The observed levels of limonene production (horizontal axis) are compared with predicted levels (vertical axis) in fold change (FC) for each RBS combination using leave-one-out cross-validation with a resulting performance of  $Q^2 = 0.48$ . The blue dashed line is the linear fitting of the points.

144

145 **S10. Re-screening of pMVA2lib high producers from 1 ml screen**

146

147



148

149


150 **Figure S10.** Re-screen of high producer variants from the pMVA2 libraries. High producing variants from the

151 pMVA2lib1/2 were re-introduced into cells, along with pGL403, and grown in triplicate to confirm their

152 production titres relative to starting plasmid pMVA2.

153

154 **S11. Comparison of production titres from individual clones of pMVA2lib1 at**  
155 **the 1 ml and 5 ml scale**  
156



157  
158  
159 **Figure S11.** Comparison of limonene production titres for members of pMVA2lib1 at the 1 and 5 ml scaled.  
160 Titres produced by individual clones from RBS library pMVA2lib2 when grown at either the 1 ml or 5  
161 ml scale. As titres for 1ml cultures increase titres at 5ml screening scale tend to increase as well. This  
162 positive association however is rather weak as indicated by a non-significant ( $p=0.218$ ) Pearson  
163 coefficient  $r=0.274$ .  
164

165 **S12. Comparison of RBS sequences pMVA2lib1 screened at the 1 ml and 5 ml**  
166 **scale**  
167

Low producers  $FC > Q_2$

pMVA2 1 mL




pMVA2 5 mL



168

169 **Figure. S12.** Comparison of frequency of nucleotides at RBS positions for high producers in the pMVA2lib1  
170 library when screened at 1 mL or 5 mL scale. A) Distribution for the *Ef-mvaE*, *Ef-mvaS*, *Sp-mvaK1* and *Ec-idi*  
171 RBS sequences for high producers in the pMVA2 library (FC > upper quartile); B) Distribution for the *Ef-mvaE*,  
172 *Ef-mvaS*, *Sp-mvaK1* and *Ec-idi* RBS for low producers in the pMVA2 library (FC < lower quartile). Sequence  
173 logos were generated through the weblogo service ([weblogo.berkeley.edu](http://weblogo.berkeley.edu)).

174

175 **S13. Pathway performance at 25 ml scale in baffled flasks**  
176  
177  
178

179  
180 **Figure. S13.** Comparison of limonene production titres from key pathways in 25 ml shake-flask cultures. The  
181 highest limonene producing pathways from each round of translational tuning (pGL403, pMVA2035) plus the  
182 previously published pathway (pJBEI6410) were re-tested for limonene production in 25 ml cultures in baffled  
183 flasks in either *E. coli* DH1 or DH10 $\beta$  and in EZ Rich defined media or TB. The same relative production titres  
184 were seen from the individual pathway in each condition tested, with the highest titers for each pathway  
185 observed in *E. coli* DH10 $\beta$  and TB media.  
186  
187

188 **Table S1. Enzymes used in this study**189  
190  
191**Table S1.** Enzymes used in this study.

Enzyme ID	Enzyme activity	Source	Uniprot ID	Ref
<i>Ef-mvaE</i>	Acetyl-CoA acetyltransferase/HMG-CoA reductase	<i>Enterococcus faecalis</i>	Q9FD70	1
<i>Ef-mvaS</i>	Hydroxymethylglutaryl-CoA synthase	<i>Enterococcus faecalis</i>	Q9FD71* (A110G)	2
<i>Sp-mvaK1</i>	Mevalonate kinase	<i>Streptococcus pneumoniae</i>	A0A0H2UNK6	3
<i>Sp-mvaK2</i>	Phosphomevalonate kinase	<i>Streptococcus pneumoniae</i>	A0A0I6R1S1	3
<i>Sp-mvaD</i>	Diphosphomevalonate decarboxylase	<i>Streptococcus pneumoniae</i>	A0A0B7L0J5	3
<i>Ec-idi</i>	Isopentenyl-diphosphate Delta-isomerase	<i>E. coli</i>	Q46822	4
<i>trAg-GPPS</i>	Geranyl diphosphate synthase	<i>Abies grandis</i>	Q8LKJ2	5
<i>trMs-limS</i>	4S-limonene synthase	<i>Mentha spicata</i>	Q40322	6

192 \*The enzyme *Ef-mvaS* contains a single mutation of A110G with respect to the wild type. The prefix “tr”

193 indicates that the gpps and limS genes were truncated to remove N-terminal signal peptides.

194

195 **Table S3. Machine learning validation statistics**

196  
197 **Table S3.** Coefficients of determination ( $R^2$ ,  $Q^2$ ) and root mean square errors (RMSEP, RMSECV) of prediction  
198 and 10-fold cross-validation, respectively, and p-value for permutation tests for the predictors of pGLlib and  
199 pMVA2lib1/2.

Plasmid	Statistic	Value	p-value
pGL	$R^2$	0.97	$\leq 0.001$
pGL	$Q^2$	0.87	$\leq 0.001$
pGL	RMSEP	0.09	$\leq 0.001$
pGL	RMSECV	0.47	$\leq 0.001$
pMVA2	$R^2$	0.67	$\leq 0.001$
pMVA2	$Q^2$	0.48	$\leq 0.001$
pMVA2	RMSEP	0.24	$\leq 0.001$
pMVA2	RMSECV	0.46	$\leq 0.021$

200  
201

202 **Table S5. Oligos used in this study**

203

204

**Table S5.** Oligonucleotides used in this study.

Oligo name	Sequence (5'-3')
<b>PCR primers</b>	
mvaK1trc-F	TCGTATAATGTGTGGAATTGTGAGCGGATAACAATTCAAGACAGGCTCCATTAAACATAAGG
mvaK1trc-R	CCACACATTATACGAGCCGGATGATTAATTGTCAACAGCTTAATTACGATAGCTACGCACGGTG
GPPSRBS-F	CCCTATCAGTGTAGAGAAAAAGAATTACGATCTTAAGTARRCGVGGAAAATAATGGAGTTGACTTCACAAATAC
GPPSRBS-R	AACATAATCTGCCAGACCCAG
limSRBS-F	GCATTCGTCAGAATTAGCTAGAGTAAACTAACGATCTAAGRSGVTACTAATGGAACGTCGTAGCG
limSRBS-R	TTATGCAAACGGTTCAAACAGGGTACG
pBbSeq-R2	CAGTGTGACTCTAGTAGAGAGCGTTCAC
tetprom2	GACCTCATTAAGCAGCTCTAATGC
pGL-F	GGATCCAAACTCGAGTAAGG
pGL-R	AGTGGTAAATAACTCTATCAACG
MVAlib1.1-F	GCTAAGGAGTCGCACGAGACGCCAATWGGGAGGHGGCGATGCAGACCGAACATG
MVAlib1.1-R	TAACTGGCTTGGAGGAGCGC
MVAlib1.2-F	CCTCGGTTCAAAGAGTTGGTAGC
MVAlib1.2-R	GCGACATCGTATAACGTTACTGG
MVAlib1.3-F	AGAGTATGCCGGTGTCTTATCAG
MVAlib1.3-R	GCAGTGCATCAATAATCACCACGGTTTCATATGTACGTHCBTCCTTAAAGATCTTGAATTCTGAAATTGTTATCCG
MVAlib2.1-F	GTACCCGATTGGTAAATACAAAGGTAG
MVAlib2.1-R	GGCCACCAACCAATACACAGG
MVAlib2.2-F	TGGGTCTGGCAATGCTGCTG
MVAlib2.2-R	AATTGCCAGGGCACGATCCTG
MVAlib3-F	CTGAATGATCTCGTAAACAGTAATGATTAGCGACAAAKATGAGGMGTRAAAAATGACCATTGGCATCGACAAATCAG
MVAlib3-R	GCCTGACCAACACCAACTTTTGGTCATCGTATKCCTCSTDCGTGTTAAATGGGAGCCTGTCGAAATTG
MVAlib4.1-F	ACATAGCAAAATTATCCTGATTGGTGAAC
MVAlib4.1-R	GATCTTCTGCAACAATACATGCCAG
MVAlib4.2-F	TGGTTCTGTATCAGAGCTTGATCGTC
MVAlib4.2-R	AACAATCATCCTGGCTCAGATCTTG
<b>Bridging oligos</b>	

brGL	GCTGCTGGCTGGCAGATTATGTTGCATTCGTCAAGAATTAAGCTTAGAGTAAACTAACGAT
brLP	CCGTACCCCTGTTGAACCGTTGCATAAGGATCAAACCTCGAGTAAGGATCTCCAGG
brPG	TGTTGACACTCTATCGTGATAGAGTTTTACCACTCCCTATCAGTGATAGAGAAAAGAATTCACGATCTAAGT
brMVAlib1.1-1.2	TGACTGCGCTCCCTCCAAGCCAGTTACCTCGTTCAAAGAGTTGGTAGCTCAGAGAAC
brMVAlib1.2-1.3	GGTGAATGTGAAACCGAGTAACTGTTACGATGTCGCAGAGTATGCCGGTGTCTTATCAGACCGT
brMVAlib1.3-2.1	GTACATATGAAAACCGTGGTATTGATGCACTGCGTACCCGATTGGTAAACAAAGGTAGCCTGAGC
brMVAlib2.1-2.2	GCAAGCCTGTTATTGGTGGTGGCCTGGTCTGGCAATGCTGCTGGAAC
brMVAlib2.2-3	CAATGAATCAGGATCGTGCCTGGCAATTCTGAATGATCTGCGTAAACAGTAATGATTAGCGACAAA
brMVAlib3-4.1	CGATGACCAAAAAAGTTGGTGGTCAGGCACATAGCAAAATTATCCTGATTGGTGAACATGCCG
brMVAlib4.1-4.2	TGGGTGATCTGGCATGTTGAGAAGATCTGGTCTGTATCAGAGCTTGATCGTCAGAAAGC
brMVAlib4.1-1.1	GCAAAACCAAGATCTGAGGCCAGGATGATTGTTGCTAAGGAGTCGCACGAGACGCCA

205  
206

207 **Table S6. Plasmids and strains used in this study**  
208  
209  
210**Table S6.** Plasmids and strains used in this study.

Plasmid reference	Plasmid short and systematic name	Description (Origin of replication, Antibiotic marker, Reference(s), Promoters and Operons)	Reference
pJBEI-6410	pBbA5a-MTSAe-T1f-MBI(f)-T1002i-Ptrc-trGPPS(co)-LS	p15A, Ampr, PlacUV5, MTSA, T1, MBI-f, T1002, Ptrc, trGPPS, LS	7
pMVA	pBbA5a-MTSAe-T1f-MBI(f)-T1002i	p15A, Kanr, PlacUV5, MTSA, T1, MBI-f, T1002	8
pMVA2*	pBbA1k-ES-1-K1K2Didi	p15A, Kanr, Ptrc, mvaES, Ptrc, mvaK1K2D, idi	This study
pMVA3	pBbA5k-ES-1-K1K2Didi	p15A, Kanr, PlacUV5, mvaES, Ptrc, mvaK1K2D, idi	This study
pMVA4	pBbA1k-ESK1K2Didi	p15A, Kanr, Ptrc, mvaES, mvaK1K2D, idi	This study
pMVA5	pBbA5k-ESK1K2Didi	p15A, Kanr, PlacUV5, mvaES, mvaK1K2D, idi	This study
pMVA2RBS035*	pBbA1k-ES-1-K1K2Didi	p15A, Kanr, Ptrc, mvaES, Ptrc, mvaK1K2D, idi	This study
pGL*	pBbB2a-trAgGPPS-trMsLS	pBBR, Ampr, Ptet, trAgGPPS-trMsLS	8
pGL403*	pBbB2a-trAgGPPS-trMsLS403	As pGL with optimised RBSs.	This study
Strain	Alternative designation	Genotype	Source
DH10β	NEB 10-beta	Δ(ara-leu) 7697 araD139 fhuA ΔlacX74 galK16 galE15 e14-φ80dlacZΔM15 recA1 relA1 endA1 nupG rpsL (StrR) rph spoT1 Δ(mrrhsdRMS-mcrBC)	New England Biolabs
DH1	ATCC33849	F- supE44 hsdR17 recA1 gyrA96 relA1 endA1 thi-1 lambda-	ATTC

211  
212 \*Plasmids deposited with Addgene

213 **References**

- 214 1. Wilding, E.I., Brown, J.R., Bryant, A.P., Chalker, A.F., Holmes, D.J., Ingraham, K.A., Iordanescu, S.,  
215 So, C.Y., Rosenberg, M. and Gwynn, M.N. (2000) Identification, evolution, and essentiality of the  
216 mevalonate pathway for isopentenyl diphosphate biosynthesis in gram-positive cocci. *J. Bacteriol.* 182,  
217 4319-4327.
- 218 2. Yang, J., Xian, M., Su, S., Zhao, G., Nie, Q., Jiang, X., Zheng, Y. and Liu, W. (2012) Enhancing  
219 production of bio-isoprene using hybrid MVA pathway and isoprene synthase in *E. coli*. *PLoS One*. 7,  
220 e33509.
- 221 3. Yoon, S.H., Lee, S.H., Das, A., Ryu, H.K., Jang, H.J., Kim, J.Y., Oh, D.K., Keasling, J.D. and Kim, S.W.  
222 (2009) Combinatorial expression of bacterial whole mevalonate pathway for the production of beta-  
223 carotene in *E. coli*. *J. Biotechnol.* 140, 218-226.
- 224 4. Yoon, S.H., Lee, Y.M., Kim, J.E., Lee, S.H., Lee, J.H., Kim, J.Y., Jung, K.H., Shin, Y.C., Keasling, J.D.  
225 and Kim, S.W. (2006) Enhanced lycopene production in *Escherichia coli* engineered to synthesize  
226 isopentenyl diphosphate and dimethylallyl diphosphate from mevalonate. *Biotechnol. Bioeng.* 94, 1025-  
227 1032.
- 228 5. Yang, J., Nie, Q., Ren, M., Feng, H., Jiang, X., Zheng, Y., Liu, M., Zhang, H. and Xian, M. (2013)  
229 Metabolic engineering of *Escherichia coli* for the biosynthesis of alpha-pinene. *Biotechnol. Biofuels*. 6,  
230 60.
- 231 6. Colby, S.M., Alonso, W.R., Katahira, E.J., McGarvey, D.J. and Croteau, R. (1993) 4S-limonene synthase  
232 from the oil glands of spearmint (*Mentha spicata*). cDNA isolation, characterization, and bacterial  
233 expression of the catalytically active monoterpene cyclase. *J. Biol. Chem.* 268, 23016-23024.
- 234 7. Alonso-Gutierrez, J., Chan, R., Batth, T.S., Adams, P.D., Keasling, J.D., Petzold, C.J. and Lee, T.S.  
235 (2013) Metabolic engineering of *Escherichia coli* for limonene and perillyl alcohol production. *Metab.*  
236 *Eng.* 19, 33-41.
- 237 8. Leferink, N.G., Jervis, A.J., Zebec, Z., Toogood, H.S., Hay, S., Takano, E. and Scrutton, N.S. (2016) A  
238 'plug and play' platform for the production of diverse monoterpene hydrocarbon scaffolds in *Escherichia*  
239 *coli*. *ChemistrySelect*. 1,1893-1896.